Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Receivables - Net (2016 - 2025)

Historic Receivables - Net for Collegium Pharmaceutical (COLL) over the last 10 years, with Q3 2025 value amounting to $233.9 million.

  • Collegium Pharmaceutical's Receivables - Net rose 240.44% to $233.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $233.9 million, marking a year-over-year increase of 240.44%. This contributed to the annual value of $228.5 million for FY2024, which is 2730.26% up from last year.
  • Latest data reveals that Collegium Pharmaceutical reported Receivables - Net of $233.9 million as of Q3 2025, which was up 240.44% from $213.0 million recorded in Q2 2025.
  • Over the past 5 years, Collegium Pharmaceutical's Receivables - Net peaked at $233.9 million during Q3 2025, and registered a low of $90.1 million during Q2 2021.
  • Its 5-year average for Receivables - Net is $177.9 million, with a median of $181.9 million in 2023.
  • In the last 5 years, Collegium Pharmaceutical's Receivables - Net soared by 11921.13% in 2022 and then crashed by 1520.27% in 2023.
  • Over the past 5 years, Collegium Pharmaceutical's Receivables - Net (Quarter) stood at $105.8 million in 2021, then soared by 73.01% to $183.1 million in 2022, then dropped by 1.96% to $179.5 million in 2023, then increased by 27.3% to $228.5 million in 2024, then increased by 2.37% to $233.9 million in 2025.
  • Its last three reported values are $233.9 million in Q3 2025, $213.0 million for Q2 2025, and $228.7 million during Q1 2025.